Albiglutide - Top line data from HARMONY 7 - Inferior on Efficacy to Victoza, but a competitive clinical profile overall
In the HARMONY 7 trial, although albiglutide failed to match Victoza on efficacy and the weight loss benefit as well is not great, the GI safety profile (lower nausea and vomiting) and the benefit of once weekly administration should provide the needed competitive edge. In top line data there is no mention about the skin related adverse events, which if albiglutide is able to avoid, it would help it differentiate itself from Bydureon. We await the detailed data which will be announced at upcoming diabetes conference (Table 2). Table 3 compares Albiglutide with other late stage GLP-1 analogues. A cross trial comparision of Albiglutide to Bydureon from Harmony 7 and Duration 6 study suggests.…. For more details please read our report released on November 16th comparing Albiglutide to other pipeline GLP-1 analogues.
COMPANIES MENTIONED
GlaxoSmithKline, Novo Nordisk, Amylin
GlaxoSmithKline, Novo Nordisk, Amylin
